Aadi Bioscience, Inc. (AADI) |
|
5.22 -0.02 (-0.38%)
|
09-27 16:00 |
|
Open: |
5.28 |
Pre. Close: |
5.24 |
|
High:
|
5.44 |
Low:
|
5.1801 |
|
Volume:
|
78,791 |
Market Cap:
|
128(M) |
|
|
|
Technical analysis |
as of: 2023-09-27 4:17:24 PM |
|
Short-term rate:
|
 |
| Stoxline posted a BUY today, same as yesterday. Upward movement continues. |
|
Mid-term rate:
|
  |
| Target: |
Six months: 7.41 One year: 8.45 |
| Support: |
Support1: 4.9 Support2: 4.07 |
| Resistance: |
Resistance1: 6.34 Resistance2: 7.23 |
| Pivot: |
5.4  |
| Moving Average: |
MA(5): 5.13 MA(20): 5.53
MA(100): 6.58 MA(250): 9.4 |
| MACD: |
MACD(12,26): -0.3 Signal(9): -0.2 |
| Stochastic oscillator: |
%K(14,3): 18.4 %D(3): 12.3 |
| RSI: |
RSI(14): 41.6 |
| 52-week: |
High: 14.77 Low: 4.9 |
| Average Vol(K): |
3-Month: 132 (K) 10-Days: 124 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ AADI ] has closed above bottom band by 35.9%. Bollinger Bands are 13.9% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices. |
|
|
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
5.33 - 5.35 |
5.35 - 5.38 |
|
Low:
|
4.92 - 4.95 |
4.95 - 4.97 |
|
Close:
|
5.19 - 5.24 |
5.24 - 5.28 |
|
Company Description |
|
Aadi Bioscience, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug candidate, FYARRO is a form of sirolimus bound to albumin. Aadi is evaluating FYARRO in cancers with known mTOR pathway activation, including tumor agnostic indications targeting specific genomic alterations that activate the mTOR pathway. The company was incorporated in 2007 and is headquartered in Pacific Palisades, California. |
Headline News |
Mon, 25 Sep 2023
Understanding Trading Halts and Resumption Protocols A Guide to ... - Best Stocks
Thu, 21 Sep 2023
Metastatic Colorectal Cancer Pipeline as Novel and Extensive 130+ Therapies Likely to Enter in the Domain - Benzinga
Wed, 20 Sep 2023
Aadi Bioscience Announces Poster Presentations at 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics - Yahoo Finance
Wed, 20 Sep 2023
Projected Market Value: mTOR Inhibitors Market Set to Reach $8.76 ... - GlobeNewswire
Wed, 20 Sep 2023
Aadi Bioscience, Inc. (NASDAQ:AADI) Short Interest Down 5.1% in ... - MarketBeat
Tue, 12 Sep 2023
BVF Inc. IL Has $2.30 Million Position in Aadi Bioscience, Inc ... - MarketBeat
|
Financial Analysis |
| Price to Book Value: |
Outperform |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Underperform |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Underperform |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Underperform |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Neutral |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. |
25 (M) |
| Shares Float |
16 (M) |
|
% Held by Insiders
|
12.5 (%) |
|
% Held by Institutions
|
60.7 (%) |
|
Shares Short
|
623 (K) |
|
Shares Short P.Month
|
1,090 (K) |
Stock Financials |
|
EPS
|
-2.31 |
|
EPS Est Next Qtl
|
0 |
|
EPS Est This Year
|
0 |
|
EPS Est Next Year
|
0 |
|
Book Value (p.s.)
|
5.36 |
|
Profit Margin (%)
|
-285.9 |
|
Operating Margin (%)
|
-310.5 |
|
Return on Assets (ttm)
|
-29.9 |
|
Return on Equity (ttm)
|
-51.3 |
|
Qtrly Rev. Growth
|
80.4 |
|
Gross Profit (p.s.)
|
-0.77 |
|
Sales Per Share
|
0.87 |
|
EBITDA (p.s.)
|
-2.73 |
|
Qtrly Earnings Growth
|
0 |
|
Operating Cash Flow
|
-58 (M) |
|
Levered Free Cash Flow
|
-37 (M) |
Stock Valuations |
|
PE Ratio
|
-2.26 |
|
PEG Ratio
|
0 |
|
Price to Book value
|
0.97 |
|
Price to Sales
|
5.94 |
|
Price to Cash Flow
|
-2.23 |
Stock Dividends |
|
Dividend
|
0 |
|
Forward Dividend
|
0 |
|
Dividend Yield
|
0% |
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
Your Ad Here
|
|
